|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Land | ||||||||||||||||||||
| Buildings | ||||||||||||||||||||
| Equipment | ||||||||||||||||||||
| Construction in progress | ||||||||||||||||||||
| Property and equipment, at cost | ||||||||||||||||||||
| Accumulated depreciation | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Investments of insurance subsidiaries | ||||||||||||||||||||
| Investments in and advances to affiliates | ||||||||||||||||||||
| Goodwill and other intangible assets | ||||||||||||||||||||
| Right-of-use operating lease assets | ||||||||||||||||||||
| Other | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued salaries | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Long-term debt due within one year | ||||||||||||||||||||
| Short-term borrowings and long-term debt due within one year | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt, less debt issuance costs and discounts of $451and $436 | ||||||||||||||||||||
| Professional liability risks | ||||||||||||||||||||
| Right-of-use operating lease obligations | ||||||||||||||||||||
| Income taxes and other liabilities | ||||||||||||||||||||
| Stockholders' (deficit) equity: | ||||||||||||||||||||
| Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 217,963,300 shares - 2026 and 224,605,100 shares - 2025 | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained deficit | ||||||||||||||||||||
| Stockholders' deficit attributable to HCA Healthcare, Inc. | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total stockholders' (deficit) equity | ||||||||||||||||||||
| Total liabilities and stockholders' (deficit) equity | ||||||||||||||||||||
Loading...
